Resverlogix (TSE:RVX) has released an update.
Don't Miss our Black Friday Offers:
- Unlock your investing potential with TipRanks Premium - Now At 40% OFF!
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter
At the European Society of Cardiology Congress 2024, Resverlogix Corp. highlighted the cardioprotective benefits of its drug apabetalone, which, in conjunction with other treatments, showed a 63% reduction in major adverse cardiac events and heart failure in patients. The company’s data promoted the drug as a beneficial addition to current treatments for cardiovascular and metabolic diseases, with the potential to improve patient outcomes significantly.
For further insights into TSE:RVX stock, check out TipRanks’ Stock Analysis page.
